Securian Asset Management Inc. Has $1.22 Million Holdings in Axon Enterprise, Inc $AXON

Securian Asset Management Inc. lessened its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 44.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,140 shares of the biotechnology company’s stock after selling 1,686 shares during the quarter. Securian Asset Management Inc.’s holdings in Axon Enterprise were worth $1,215,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Vicus Capital increased its stake in Axon Enterprise by 3.7% in the 3rd quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 14 shares during the last quarter. Evergreen Capital Management LLC boosted its stake in shares of Axon Enterprise by 3.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after buying an additional 15 shares during the last quarter. NorthCrest Asset Manangement LLC grew its holdings in shares of Axon Enterprise by 5.4% in the 3rd quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 16 shares in the last quarter. WPG Advisers LLC increased its position in shares of Axon Enterprise by 9.8% in the third quarter. WPG Advisers LLC now owns 190 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 17 shares during the last quarter. Finally, Monte Financial Group LLC increased its position in shares of Axon Enterprise by 5.5% in the third quarter. Monte Financial Group LLC now owns 325 shares of the biotechnology company’s stock valued at $233,000 after acquiring an additional 17 shares during the last quarter. Institutional investors own 79.08% of the company’s stock.

Wall Street Analyst Weigh In

AXON has been the subject of several recent research reports. Morgan Stanley set a $600.00 price target on Axon Enterprise in a research report on Thursday, May 7th. Craig Hallum reissued a “buy” rating and issued a $820.00 price objective on shares of Axon Enterprise in a report on Wednesday, February 25th. Piper Sandler lowered their target price on shares of Axon Enterprise from $690.00 to $674.00 and set an “overweight” rating on the stock in a report on Thursday, May 7th. The Goldman Sachs Group set a $535.00 price target on shares of Axon Enterprise in a research report on Thursday, May 7th. Finally, Citigroup reiterated a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, February 25th. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $712.75.

Axon Enterprise Stock Down 0.2%

AXON stock opened at $393.66 on Wednesday. Axon Enterprise, Inc has a 1-year low of $339.01 and a 1-year high of $885.91. The business’s 50 day simple moving average is $443.50 and its 200 day simple moving average is $521.18. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $31.73 billion, a PE ratio of 158.10, a PEG ratio of 9.28 and a beta of 1.44.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.01. The business had revenue of $807.35 million during the quarter, compared to the consensus estimate of $778.91 million. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The company’s quarterly revenue was up 33.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.47 EPS. As a group, research analysts anticipate that Axon Enterprise, Inc will post 1.41 EPS for the current year.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, insider Isaiah Fields sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $535.01, for a total transaction of $1,070,020.00. Following the completion of the sale, the insider directly owned 55,588 shares in the company, valued at $29,740,135.88. This trade represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Erika Nardini sold 198 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $506.58, for a total value of $100,302.84. Following the sale, the director owned 1,946 shares of the company’s stock, valued at approximately $985,804.68. This represents a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 13,855 shares of company stock worth $7,109,828 in the last ninety days. Insiders own 5.70% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.